Segall Bryant & Hamill’s Gentex GNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-257,822
Closed -$7.3M – 603
2025
Q3
$7.3M Sell
257,822
-333,569
-56% -$8.86M 0.1% 275
2025
Q2
$13M Buy
591,391
+98,480
+20% +$2.15M 0.18% 184
2025
Q1
$11.5M Buy
492,911
+29,752
+6% +$761K 0.18% 183
2024
Q4
$13.3M Buy
463,159
+15,689
+4% +$470K 0.18% 168
2024
Q3
$13.3M Buy
447,470
+14,278
+3% +$443K 0.18% 183
2024
Q2
$14.6M Buy
433,192
+47,439
+12% +$1.64M 0.26% 124
2024
Q1
$13.9M Sell
385,753
-8,740
-2% -$302K 0.26% 136
2023
Q4
$12.9M Buy
394,493
+72,326
+22% +$2.23M 0.25% 148
2023
Q3
$10.5M Sell
322,167
-68,412
-18% -$2.19M 0.12% 210
2023
Q2
$11.4M Buy
390,579
+16,381
+4% +$452K 0.12% 217
2023
Q1
$10.5M Buy
374,198
+63,292
+20% +$1.78M 0.11% 223
2022
Q4
$8.48M Buy
+310,906
New +$8.3M 0.09% 245
2021
Q4
– Sell
-76,532
Closed -$2.52M – 646
2021
Q3
$2.52M Buy
76,532
+2,522
+3% +$81.4K 0.02% 436
2021
Q2
$2.45M Buy
74,010
+30,833
+71% +$1.07M 0.02% 439
2021
Q1
$1.54M Sell
43,177
-43,747
-50% -$1.55M 0.02% 500
2020
Q4
$2.95M Buy
86,924
+19,298
+29% +$595K 0.03% 370
2020
Q3
$1.74M Buy
+67,626
New +$1.8M 0.02% 410

Other funds holding GNTX

Segall Bryant & Hamill's GNTX Position: Q4 2025 in Review

Segall Bryant & Hamill sold out of Gentex (GNTX) in Q4 2025, closing a stake of 257,822 shares — an estimated $7.3M sold.

Segall Bryant & Hamill first reported a position in GNTX in Q3 2020 and held it in 17 quarters. The position peaked at $14.6M in Q2 2024. 526 funds tracked by Wall St. Rank hold GNTX as of Q4 2025.

  • Segall Bryant & Hamill reported no remaining Gentex position as of Q4 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 257,822 Gentex shares in Q4 2025, an estimated $7.3M.
  • Segall Bryant & Hamill first reported a position in Gentex in Q3 2020 and held it in 17 quarters.
  • Segall Bryant & Hamill's Gentex position peaked at $14.6M in Q2 2024.
  • 526 funds tracked by Wall St. Rank held Gentex as of Q4 2025.

Based on Segall Bryant & Hamill's 13F filing for Q4 2025, filed 13 Feb 2026.